FDA Granted Regulatory Designations to SOT106

The regulatory body issued Fast Track and Orphan Drug status to SOTIO Biotech for its new cancer treatment candidate.

Updated on Sept. 23, 2026 in Cancer

Isometric editorial illustration showing a complex molecular structure of spheres and rods, symbolizing pharmaceutical development. — The U.S. Food and Drug Administration has granted Fast Track and Orphan Drug designations to SOTIO Biotech's SOT106 cancer treatment candidate. AI Illustration. Upload story photo >

Live Poll

Should the government do more to expedite the approval process for new rare disease treatments?

The U.S. Food and Drug Administration has granted both Fast Track and Orphan Drug designations to SOT106, an antibody-drug conjugate developed by SOTIO Biotech. These designations aim to accelerate the development of the drug for treating soft tissue sarcoma and osteosarcoma.

Why it matters

These regulatory designations provide SOTIO Biotech with incentives and enhanced engagement with the FDA, which are essential for navigating the complex approval process for therapies targeting rare diseases.

SOT106 is an antibody-drug conjugate that targets leucine-rich repeat-containing 15, utilizing a beta-glucuronidase-cleavable linker designed for stable circulation and selective tumor payload release.

The players

Food and Drug Administration

The U.S. federal agency is responsible for protecting public health by regulating human and veterinary drugs, biological products, and medical devices.

SOTIO Biotech

This clinical-stage biopharmaceutical company focuses on the development of novel cancer therapies and is owned by the PPF Group.

The details

SOT106 functions by pairing an LRRC15-targeting antibody with site-specific conjugation technology to ensure precise delivery. By focusing on the tumor environment, the drug is intended to reduce off-target toxicity in patients.

The FDA granted the Orphan Drug and Fast Track designations on September 23, 2026.
SOTIO Biotech expects to initiate a first-in-human clinical trial for SOT106 later in 2026.

The Big Picture

This development follows the precedent set by the Orphan Drug Act, which offers manufacturers financial and regulatory incentives to develop treatments for rare medical conditions.

These designations may expedite the clinical trial timeline for SOT106, potentially bringing a new therapeutic option to patients with rare sarcomas sooner than originally anticipated. The specific impact on individual treatment plans will depend on the upcoming safety and efficacy results from the trial.

The takeaway

The granting of these designations signifies a critical step forward in the development of targeted therapies for rare bone and soft tissue cancers. It highlights the continued importance of regulatory support in moving experimental antibody-drug conjugates from the lab to human trials.